What is the clinical effect of levodopa inhalation powder spray (Inbrija)?

Levodopa inhalation powder (Inbrija) has been shown in clinical studies to significantly improve the symptoms of Parkinson's disease patients in the "OFF" phase. Two major studies examined the effectiveness of levodopa inhalation powder, using the Unified Parkinson's Disease Rating Scale (UPDRS, Part III) as an assessment tool. The first study involved 226 patients who received 12 weeks of standard treatment with levodopa and a dopa decarboxylase inhibitor. The results of the study showed that patients who took levodopa inhalation powder during the "OFF" period improved by an average of 10 points on the symptom scale after 30 minutes, while patients who took a placebo improved by only 6 points. In addition, 71% of patients treated with levodopa inhalation powder reported an improvement in their symptoms, compared with 46% of patients taking placebo.

A second study further supports the clinical efficacy of levodopa inhalation powder. The study, which involved 77 patients who received four weeks of standard treatment, showed that patients who took levodopa inhalation powder during the "OFF" period improved their scores by an average of 10 points after 10 to 60 minutes, while those who took a placebo improved by only 3 points. These data show that levodopa inhalation powder can quickly and significantly relieve the "OFF" phase symptoms of Parkinson's disease patients and help them restore motor function in a short time.

Generally speaking, levodopa inhalation powder spray can quickly transport levodopa to the brain through inhalation administration to make up for the lack of dopamine levels, thereby effectively improving the motor symptoms of patients with Parkinson's disease. Clinical research data confirms that levodopa inhalation powder not only works quickly but is also significantly better than placebo, providing a reliable treatment option for patients with Parkinson's disease. However, patients still need to pay attention to possible side effects during use and use the medication rationally under the guidance of a doctor to ensure the best therapeutic effect and safety.

Reference link:https://www.ema.europa.eu/en/medicines/human/EPAR/inbrija